Biocon wins OK for Herceptin biosimilar; Dicerna, Argos and NephroGenex set IPO terms;

@FierceBiotech: Alzheimer's expert claims he was wooed into biotech insider scandal. Article | Follow @FierceBiotech

@JohnCFierce: First Pfizer, now J&J. Jim Allison is a big draw. Industry giants join MD Anderson's star team for immunotherapies. Story | Follow @JohnCFierce

@DamianFierce: If Amarin's latest Vascepa appeal fails, it has two more FDA rungs to climb, agency says. More | Follow @DamianFierce

@EmilyMFierce: Cleveland Clinic researchers find protein responsible for amyloid buildup, memory loss in Alzheimer's. Story | Follow @EmilyMFierce

> India's Biocon and Mylan ($MYL) have won approval for a biosimilar of Herceptin and plan to launch it in the subcontinent next month. Story

> Dicerna Pharmaceuticals has set its terms, laying out plans to sell 5 million shares for $11 to $13 a share. Story

> Durham, NC-based Argos Therapeutics is looking to raise about $60 million from the sale of 4.1 million shares in an IPO priced at $13 to $15 a share. Report

> NephroGenex has set terms for its IPO, planning to sell 3.1 million shares at $12 to $14 a share. At the mid-range the offering would raise about $40 million. Story

Medical Device News

@FierceMedDev: J&J's Q4 looked great for orthopedics, but less so for diabetes and Dx. More | Follow @FierceMedDev

@MarkHFierce: Covidien said slow market growth led to its decision to abandon a renal denervation program. Story | Follow @MarkHFierce

@MichaelGFierce: Myriad will sell breast cancer Dx from Siemens spinoff in Europe. Item | Follow @MichaelGFierce

@EmilyWFierce: Boston physician questions medical devices used during minimally invasive hysterectomies. Article | Follow @EmilyWFierce

> Tandem expands its voluntary recall of the t:slim insulin pump. Report

> Medtronic's transcatheter heart valve scores early FDA approval. News

Pharma News

@FiercePharma: Saline shortage: FDA works with Baxter, Hospira and Braun. More | Follow @FiercePharma

@TracyStaton: J&J, Glaxo tops in pharma social media, but smaller companies rate highly, too. Report | Follow @TracyStaton

@EricPFierce: Roche says in an email that the temporary shortage of Tamiflu is over. The FDA says so too. More | Follow @EricPFierce

@CarlyHFierce: Forest's Q3 numbers are out - take a look. Release | Follow @CarlyHFierce

> Turbocharged pharma growth drives J&J's 2013 sales to $71B. Report

> Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics. News

> NuPathe nixes Endo's buyout offer to hook up with Teva. Story

Pharma Manufacturing News

> Shire has a partially built plant for sale after unloading Dermagraft. News

> Aurobindo deal with Actavis accelerates its expansion of sterile injectables biz. Story

> FDA recall questions the sterility of eye drops made in Vietnam. Report

> Saline shortage: FDA works with Baxter, Hospira and Braun. More

> Genentech resolves plant backup quickly but timing was bad. Article

> Novartis manufacturing gets more jobs in major restructuring. Item

Biotech Research News

> Omnibus bill to restore $1B in funding to NIH. Story

> Microparticle therapy restores damaged tissue after a heart attack. Report

> AstraZeneca, Bristol-Myers bestow $5M on diabetes research program. Item

> Existing antiviral drug could treat H7N9 flu. Article

> Innovimmune inhibitor prevents multiple sclerosis in mice. More

> Alzheimer's research blames a protein for amyloid buildup, memory loss. News

CRO News

> Patheon soars in its last year as a public CMO. Item

> AMRI: Burlington 'money pit' is now a springboard. More

> Device CRO NAMSA rolls into the U.K. with Medvance buyout. Article

> Harlan targets India with latest animal model expansion. Story

> Parexel ups its expectations after a late-year stumble. Report

> BioClinica preps for another merger as CRO consolidation marches on. Article

Biotech IT News

> Record year at PLOS ONE creates new challenges for data scientists. Item

> Regeneron to sequence 100K exomes and link data to EHRs to speed drug discovery. Story

> BioClinica to go through second merger since being taken private last year. More

> European Union makes $40M available for development of bioinformatics tools. Article

> Illumina hits the $1,000 genome mark with a big-data 'cannonball.' Story

> FDA publishes a slice of social media guidance as the deadline for a full policy nears. Report